About Tasigna

Tasigna Mechanism of Action

View an animation of the mechanism of action for Tasigna (nilotinib).

Tasigna is a next generation Bcr-Abl inhibitor for Ph+ CML. Tasigna was specifically designed to be a highly selective inhibitor of Bcr-Abl, the key cause and driver of Ph+ CML, and its mutations.
This animation shows how Tasigna binds Bcr-Abl with greater selectivity than imatinib, in vitro, and remains tightly bound to Bcr-Abl, causing inhibition of kinase activity and death of leukemic cells.

• Prescribing Tasigna
• Tasigna Efficacy
• Tasigna Safety and Tolerability
• European Summary of Product Characteristics
• Tasigna Mechanism of Action
• How to Dose